Cargando…

Targeting Pulmonary Hypertension Caused by Pulmonary Fibrosis: A Promising Natural Killer T Cell–based Therapy

Detalles Bibliográficos
Autores principales:	Wang, Zi-Hao, Zhou, Qiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037488/ https://www.ncbi.nlm.nih.gov/pubmed/36638561 http://dx.doi.org/10.1164/rccm.202211-2134LE

Ejemplares similares

The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection
por: Rajaram, Sanjeeth, et al.
Publicado: (2020)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Isoniazid and Pulmonary Fibrosis
por: Chung, Chae Uk, et al.
Publicado: (2015)

BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Chen, Lingdan, et al.
Publicado: (2020)

Neurolymphomatosis Caused by Nasal-type Extranodal Natural Killer/T-cell Lymphoma
por: Yi, Fang-Fang, et al.
Publicado: (2017)

Treatment of Pulmonary Hypertension: Is Triple Therapy Necessarily Better than Monotherapy?
por: Sun, Xishi, et al.
Publicado: (2021)

Can Pulmonary Arterial Compliance Be a Prognostic Marker for Pulmonary Hypertension?
por: Wu, Yanjuan, et al.
Publicado: (2023)

Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)
por: Farmakis, Ioannis T., et al.
Publicado: (2022)

The Potential Application and Promising Role of Targeted Therapy in Pulmonary Arterial Hypertension
por: Hsieh, Meng-Chien Willie, et al.
Publicado: (2022)

Cognitive Dysfunction in Patients with Pulmonary Hypertension
por: Yuan, Ping, et al.
Publicado: (2022)

Effect of COVID-19 in Pulmonary Hypertension
por: Jha, Ajay Kumar
Publicado: (2022)

Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis?
por: Huang, Jin-Xian, et al.
Publicado: (2022)

Novel Insight into Pulmonary Fibrosis and Long COVID
por: Kamp, Jan C., et al.
Publicado: (2023)

Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Weatherald, Jason, et al.
Publicado: (2021)

The Promises of Natural Killer Cell Therapy in Endometriosis
por: Hoogstad-van Evert, Janneke, et al.
Publicado: (2022)

The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
por: Fastrès, Aline, et al.
Publicado: (2017)

Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse
por: Johannson, Kerri A., et al.
Publicado: (2022)

Reply: Transitioning endothelial cells contribute to pulmonary fibrosis
por: Wu, Xiuju, et al.
Publicado: (2023)

Spontaneous pulmonary hypertension in genetic mouse models of natural killer cell deficiency
por: Rätsep, Matthew T., et al.
Publicado: (2018)

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection
por: Zeng, Guangting, et al.
Publicado: (2023)

Co-profiling reveals distinct patterns of genomic chromatin accessibility and gene expression in pulmonary hypertension caused by chronic hypoxia
por: Yu, Dongdong, et al.
Publicado: (2023)

Reply to Chen et al.: BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Provencher, Steeve, et al.
Publicado: (2020)

Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
por: Duitman, JanWillem, et al.
Publicado: (2019)

Pulmonary Hypertension in Glycogen Storage Disease Type II
por: Li, Hui-Ping, et al.
Publicado: (2018)

Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?
por: Zheng, Zhenzhen, et al.
Publicado: (2021)

Comparing Transbronchial Cryobiopsy and Surgical Biopsy in Idiopathic Pulmonary Fibrosis
por: Quadrelli, Silvia, et al.
Publicado: (2019)

Comments on COVID-19 Vaccination and Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kang, Tianlun, et al.
Publicado: (2022)

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?
por: Cottin, Vincent, et al.
Publicado: (2022)

Progressive Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
por: Rose, Jonathan A., et al.
Publicado: (2022)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Learning curve and analysis of curative effects after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Hong, Cheng, et al.
Publicado: (2023)

Reply to Weatherald et al.: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Badagliacca, Roberto, et al.
Publicado: (2021)

Prognostic Value of Exercise as Compared to Resting Pulmonary Hypertension in Patients with Normal or Mildly Elevated Pulmonary Arterial Pressure
por: Douschan, Philipp, et al.
Publicado: (2022)

ACE2, a promising therapeutic target for pulmonary hypertension
por: Shenoy, Vinayak, et al.
Publicado: (2011)

Initial Triple Combination Therapy for Intermediate-and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?
por: Jin, Qi, et al.
Publicado: (2021)

Patient Registries in Idiopathic Pulmonary Fibrosis: Don't Forget Socioeconomic Status
por: Sesé, Lucile, et al.
Publicado: (2020)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Bellaye, Pierre-Simon, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Moran-Mendoza, Onofre
Publicado: (2022)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p51t6sq3qivmilgpb20fvpbc4e